|
1
|
Sung H, Ferlay J, Siegel RL, Laversanne M,
Soerjomataram I, Jemal A and Bray F: Global cancer statistics 2020:
GLOBOCAN estimates of incidence and mortality worldwide for 36
cancers in 185 countries. CA Cancer J Clin. 71:209–249. 2021.
View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Li N, Lu B, Luo C, Cai J, Lu M, Zhang Y,
Chen H and Dai M: Incidence, mortality, survival, risk factor and
screening of colorectal cancer: A comparison among China, Europe,
and northern America. Cancer Lett. 522:255–268. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Lynch JP and Hoops TC: The genetic
pathogenesis of colorectal cancer. Hematol Oncol Clin North Am.
16:775–810. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Biller LH and Schrag D: Diagnosis and
treatment of metastatic colorectal cancer: A review. JAMA.
325:669–685. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Keum N and Giovannucci E: Global burden of
colorectal cancer: Emerging trends, risk factors and prevention
strategies. Nat Rev Gastroenterol Hepatol. 16:713–732. 2019.
View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Patel SG, Karlitz JJ, Yen T, Lieu CH and
Boland CR: The rising tide of early-onset colorectal cancer: A
comprehensive review of epidemiology, clinical features, biology,
risk factors, prevention, and early detection. Lancet Gastroenterol
Hepatol. 7:262–274. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Jakobsson HE, Rodríguez-Piñeiro AM,
Schütte A, Ermund A, Boysen P, Bemark M, Sommer F, Bäckhed F,
Hansson GC and Johansson ME: The composition of the gut microbiota
shapes the colon mucus barrier. EMBO Rep. 16:164–177. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Yang J, Wei H, Zhou Y, Szeto CH, Li C, Lin
Y, Coker OO, Lau HCH, Chan AWH, Sung JJY and Yu J: High-fat diet
promotes colorectal tumorigenesis through modulating gut microbiota
and metabolites. Gastroenterology. 162:135–149.e2. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Liu W, Zhang R, Shu R, Yu J, Li H, Long H,
Jin S, Li S, Hu Q, Yao F, et al: Study of the relationship between
microbiome and colorectal cancer susceptibility using 16SrRNA
sequencing. Biomed Res Int. 2020:78283922020.PubMed/NCBI
|
|
10
|
Vacante M, Ciuni R, Basile F and Biondi A:
Gut microbiota and colorectal cancer development: A closer look to
the adenoma-carcinoma sequence. Biomedicines. 8:4892020. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Mima K, Nishihara R, Qian ZR, Cao Y,
Sukawa Y, Nowak JA, Yang J, Dou R, Masugi Y, Song M, et al:
Fusobacterium nucleatum in colorectal carcinoma tissue and patient
prognosis. Gut. 65:1973–1980. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Lucas C, Barnich N and Nguyen HTT:
Microbiota, inflammation and colorectal cancer. Int J Mol Sci.
18:13102017. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Hanus M, Parada-Venegas D, Landskron G,
Wielandt AM, Hurtado C, Alvarez K, Hermoso MA, López-Köstner F and
De la Fuente M: Immune system, microbiota, and microbial
metabolites: The unresolved triad in colorectal cancer
microenvironment. Front Immunol. 12:6128262021. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Dalal N, Jalandra R, Bayal N, Yadav AK,
Harshulika, Sharma M, Makharia GK, Kumar P, Singh R, Solanki PR and
Kumar A: Gut microbiota-derived metabolites in CRC progression and
causation. J Cancer Res Clin Oncol. 147:3141–3155. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Alhinai EA, Walton GE and Commane DM: The
role of the gut microbiota in colorectal cancer causation. Int J
Mol Sci. 20:52952019. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Yachida S, Mizutani S, Shiroma H, Shiba S,
Nakajima T, Sakamoto T, Watanabe H, Masuda K, Nishimoto Y, Kubo M,
et al: Metagenomic and metabolomic analyses reveal distinct
stage-specific phenotypes of the gut microbiota in colorectal
cancer. Nat Med. 25:968–976. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Lu S, Han L, Hu X, Sun T, Xu D, Li Y, Chen
Q, Yao W, He M, Wang Z, et al: N6-methyladenosine reader IMP2
stabilizes the ZFAS1/OLA1 axis and activates the Warburg effect:
Implication in colorectal cancer. J Hematol Oncol. 14:1882021.
View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Jonsson AL and Bäckhed F: Role of gut
microbiota in atherosclerosis. Nat Rev Cardiol. 14:79–87. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Shuwen H, Yinhang W, Xingming Z, Jing Z,
Jinxin L, Wei W and Kefeng D: Using whole-genome sequencing (WGS)
to plot colorectal cancer-related gut microbiota in a population
with varied geography. Gut Pathog. 14:502022. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Zhang C, Zhou S, Chang H, Zhuang F, Shi Y,
Chang L, Ai W, Du J, Liu W, Liu H, et al: Metabolomic profiling
identified serum metabolite biomarkers and related metabolic
pathways of colorectal cancer. Dis Markers. 2021:68588092021.
View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Gu J, Xiao Y, Shu D, Liang X, Hu X, Xie Y,
Lin D and Li H: Metabolomics analysis in serum from patients with
colorectal polyp and colorectal cancer by 1H-NMR
spectrometry. Dis Markers. 2019:34918522019. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Luo XJ, Zhao Q, Liu J, Zheng JB, Qiu MZ,
Ju HQ and Xu RH: Novel genetic and epigenetic biomarkers of
prognostic and predictive significance in stage II/III colorectal
cancer. Mol Ther. 29:587–596. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Rebersek M: Gut microbiome and its role in
colorectal cancer. BMC Cancer. 21:13252021. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Vymetalkova V, Vodicka P, Vodenkova S,
Alonso S and Schneider-Stock R: DNA methylation and chromatin
modifiers in colorectal cancer. Mol Aspects Med. 69:73–92. 2019.
View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Zhang C, Wang XY, Zhang P, He TC, Han JH,
Zhang R, Lin J, Fan J, Lu L, Zhu WW, et al: Cancer-derived exosomal
HSPC111 promotes colorectal cancer liver metastasis by
reprogramming lipid metabolism in cancer-associated fibroblasts.
Cell Death Dis. 13:572022. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Vernia F, Longo S, Stefanelli G, Viscido A
and Latella G: Dietary factors modulating colorectal
carcinogenesis. Nutrients. 13:1432021. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Bian X, Liu R, Meng Y, Xing D, Xu D and Lu
Z: Lipid metabolism and cancer. J Exp Med. 218:e202016062021.
View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Munir R, Lisec J, Swinnen JV and Zaidi N:
Lipid metabolism in cancer cells under metabolic stress. Br J
Cancer. 120:1090–1098. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Tomonaga N, Manabe Y, Aida K and Sugawara
T: Dietary ceramide 2-aminoethylphosphonate, a marine
sphingophosphonolipid, improves skin barrier function in hairless
mice. Sci Rep. 10:138912020. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Vučetić M, Cormerais Y, Parks SK and
Pouysségur J: The central role of amino acids in cancer redox
homeostasis: Vulnerability points of the cancer redox code. Front
Oncol. 7:3192017. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Vettore L, Westbrook RL and Tennant DA:
New aspects of amino acid metabolism in cancer. Br J Cancer.
122:150–156. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Jiang F, Zhang Z, Zhang Y, Pan X, Yu L and
Liu S: L-carnitine ameliorates cancer cachexia in mice partly via
the carnitine palmitoyltransferase-associated PPAR-γ signaling
pathway. Oncol Res Treat. 38:511–516. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Zeller G, Tap J, Voigt AY, Sunagawa S,
Kultima JR, Costea PI, Amiot A, Böhm J, Brunetti F, Habermann N, et
al: Potential of fecal microbiota for early-stage detection of
colorectal cancer. Mol Syst Biol. 10:7662014. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Weir TL, Manter DK, Sheflin AM, Barnett
BA, Heuberger AL and Ryan EP: Stool microbiome and metabolome
differences between colorectal cancer patients and healthy adults.
PLoS One. 8:e708032013. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Clos-Garcia M, Garcia K, Alonso C,
Iruarrizaga-Lejarreta M, D'Amato M, Crespo A, Iglesias A, Cubiella
J, Bujanda L and Falcón-Pérez JM: Integrative analysis of fecal
metagenomics and metabolomics in colorectal cancer. Cancers
(Basel). 12:11422020.2020. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Chen F, Dai X, Zhou CC, Li KX, Zhang YJ,
Lou XY, Zhu YM, Sun YL, Peng BX and Cui W: Integrated analysis of
the faecal metagenome and serum metabolome reveals the role of gut
microbiome-associated metabolites in the detection of colorectal
cancer and adenoma. Gut. 71:1315–1325. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Tanoue T, Morita S, Plichta DR, Skelly AN,
Suda W, Sugiura Y, Narushima S, Vlamakis H, Motoo I, Sugita K, et
al: A defined commensal consortium elicits CD8 T cells and
anti-cancer immunity. Nature. 565:600–605. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Zhao S, Gao G, Li W, Li X, Zhao C, Jiang
T, Jia Y, He Y, Li A, Su C, et al: Antibiotics are associated with
attenuated efficacy of anti-PD-1/PD-L1 therapies in Chinese
patients with advanced non-small cell lung cancer. Lung Cancer.
130:10–17. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Ogretmen B: Sphingolipid metabolism in
cancer signalling and therapy. Nat Rev Cancer. 18:33–50. 2018.
View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Govindarajah N, Clifford R, Bowden D,
Sutton PA, Parsons JL and Vimalachandran D: Sphingolipids and acid
ceramidase as therapeutic targets in cancer therapy. Crit Rev Oncol
Hematol. 138:104–111. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Hayase E and Jenq RR: Role of the
intestinal microbiome and microbial-derived metabolites in immune
checkpoint blockade immunotherapy of cancer. Genome Med.
13:1072021. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Kim S, Covington A and Pamer EG: The
intestinal microbiota: Antibiotics, colonization resistance, and
enteric pathogens. Immunol Rev. 279:90–105. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Lavelle A and Sokol H: Gut
microbiota-derived metabolites as key actors in inflammatory bowel
disease. Nat Rev Gastroenterol Hepatol. 17:223–237. 2020.
View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Azuma K, Xiang H, Tagami T, Kasajima R,
Kato Y, Karakawa S, Kikuchi S, Imaizumi A, Matsuo N, Ishii H, et
al: Clinical significance of plasma-free amino acids and tryptophan
metabolites in patients with non-small cell lung cancer receiving
PD-1 inhibitor: A pilot cohort study for developing a prognostic
multivariate model. J Immunother Cancer. 10:e0044202022. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Riquelme E, Zhang Y, Zhang L, Montiel M,
Zoltan M, Dong W, Quesada P, Sahin I, Chandra V, San Lucas A, et
al: Tumor microbiome diversity and composition influence pancreatic
cancer outcomes. Cell. 178:795–806.e12. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Botticelli A, Vernocchi P, Marini F,
Quagliariello A, Cerbelli B, Reddel S, Del Chierico F, Di Pietro F,
Giusti R, Tomassini A, et al: Gut metabolomics profiling of
non-small cell lung cancer (NSCLC) patients under immunotherapy
treatment. J Transl Med. 18:492020. View Article : Google Scholar : PubMed/NCBI
|
